When It Comes to Ovarian Cancer, KNOW Your Options.

New or suspected diagnosis of ovarian cancer

Have not yet started treatment

Potential access to new investigational immunotherapy + experts in ovarian cancer research

Supported by standard of care


When It Comes to Ovarian Cancer, KNOW Your Options

New or suspected diagnosis of ovarian cancer

Have not yet started treatment

Potential access to new investigational immunotherapy + experts in ovarian cancer research

Supported by standard of care


When It Comes to Ovarian Cancer, KNOW Your Options.

New or suspected diagnosis of ovarian cancer

Have not yet started treatment

Potential access to new investigational immunotherapy + experts in ovarian cancer research

Supported by standard of care


Immunotherapy + Standard of Care

Looking for more than just standard of care treatment*?

The OVATION-2 Study may be an option for you. The OVATION-2 Study is evaluating an investigational immunotherapy combined with traditional standard of care (chemotherapy and surgery) treatment, compared to standard of care treatment alone, in women with newly diagnosed or suspected late-stage ovarian cancer.

*Standard of care treatment — Standard of care, or best practice, is a guideline for the appropriate treatment of a condition, as established by formal or informal consensus among experts on that condition. Basically, the standard of care for the treatment of a disease is whatever most physicians agree is the best way to treat that disease.

If you have not yet started standard of care treatment, this study may be an option for you.


Immunotherapy + Standard of Care

Looking for more than just standard of care treatment*?

The OVATION-2 Study may be an option for you. The OVATION-2 Study is evaluating an investigational immunotherapy combined with traditional standard of care (chemotherapy and surgery) treatment, compared to standard of care treatment alone, in women with newly diagnosed or suspected late-stage ovarian cancer.

*Standard of care treatment — Standard of care, or best practice, is a guideline for the appropriate treatment of a condition, as established by formal or informal consensus among experts on that condition. Basically, the standard of care for the treatment of a disease is whatever most physicians agree is the best way to treat that disease.

If you have not yet started standard of care treatment, this study may be an option for you.


Immunotherapy + Standard of Care

Looking for more than just standard of care treatment*?

The OVATION-2 Study may be an option for you. The OVATION-2 Study is evaluating an investigational immunotherapy combined with traditional standard of care (chemotherapy and surgery) treatment, compared to standard of care treatment alone, in women with newly diagnosed or suspected late-stage ovarian cancer.

*Standard of care treatment — Standard of care, or best practice, is a guideline for the appropriate treatment of a condition, as established by formal or informal consensus among experts on that condition. Basically, the standard of care for the treatment of a disease is whatever most physicians agree is the best way to treat that disease.

If you have not yet started standard of care treatment, this study may be an option for you.


To see if you may be eligible to participate and to speak with our research experts, complete our brief questionnaire.


To see if you may be eligible to participate and to speak with our research experts, complete our brief questionnaire.


ovation-2 study

The OVATION-2 Study is enrolling women who’ve just been diagnosed with, or are currently being tested for, stage 3 or 4 (advanced) ovarian, fallopian tube, or primary peritoneal cancer and are looking for an opportunity to potentially try both the standard of care (chemotherapy and surgery) treatment plus an investigational immunotherapy treatment.


ovation-2 study

The OVATION-2 Study is enrolling women who’ve just been diagnosed with, or are currently being tested for, stage 3 or 4 (advanced) ovarian, fallopian tube, or primary peritoneal cancer and are looking for an opportunity to potentially try both the standard of care (chemotherapy and surgery) treatment plus an investigational immunotherapy treatment.

You may be eligible for the OVATION-2 Study if you:

Have just been diagnosed with, or are currently being tested for, stage 3 or 4 epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Have not yet started cancer treatment

Have never received treatment for any abdominal or pelvic tumor before

Have not had any other form of cancer in the past three years

Are ambulatory (able to walk around) and generally capable of self-care

OVATION-2 Patient Information Brochure

Download our digital brochure on the OVATION-2 Study.

Download

OVATION-2 Physician Information Page

Share this with your doctor to see if the OVATION-2 Study may be right for you.

Download